scispace - formally typeset
B

Bruce M. Spiegelman

Researcher at Harvard University

Publications -  443
Citations -  172265

Bruce M. Spiegelman is an academic researcher from Harvard University. The author has contributed to research in topics: Adipose tissue & Transcription factor. The author has an hindex of 179, co-authored 434 publications receiving 158009 citations. Previous affiliations of Bruce M. Spiegelman include University of California, San Francisco & Vassar College.

Papers
More filters
Journal ArticleDOI

Degradation of the Peroxisome Proliferator-activated Receptor γ Is Linked to Ligand-dependent Activation

TL;DR: It is reported that PPARγ protein levels are significantly reduced in adipose cells and fibroblasts in response to specific ligands such as thiazolidinediones.
Journal ArticleDOI

The Transcriptional Coactivator PGC-1β Drives the Formation of Oxidative Type IIX Fibers in Skeletal Muscle

TL;DR: It is shown that transgenic expression of PGC-1beta causes a marked induction of IIX fibers, which are oxidative but have "fast-twitch" biophysical properties and are rich in mitochondria and are highly oxidative, at least in part due to coactivation by P GC-1 beta of ERRalpha and PPARalpha.
Journal ArticleDOI

C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling

TL;DR: Data indicate that C/EBPβ represses cardiomyocyte growth and proliferation in the adult mammalian heart and that reduction in C/ EBPβ is a central signal in physiologic hypertrophy and proliferation.
Journal ArticleDOI

c-fos is required for malignant progression of skin tumors

TL;DR: Experiments in which v-H-ras-expressing keratinocytes were grafted onto nude mice suggest that c-fos-deficient cells have an intrinsic defect that hinders tumorigenesis.
Journal ArticleDOI

Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α

TL;DR: It is shown that TAC in mice genetically engineered to lack PGC-1alpha leads to accelerated cardiac dysfunction, which is accompanied by signs of significant clinical heart failure, and the data suggest that elevating P GC-1 alpha activity may have therapeutic potential in the treatment of heart failure.